Holen Sie sich die Stockscreener-App
36.78
0.74%
0.27
Schlusskurs vom Vortag:
$36.51
Offen:
$40.57
24-Stunden-Volumen:
287.58K
Relative Volume:
0.41
Marktkapitalisierung:
$154.49M
Einnahmen:
$32.73M
Nettoeinkommen (Verlust:
$-19.52M
KGV:
-6.654
EPS:
-5.5275
Netto-Cashflow:
$-24.61M
1W Leistung:
+30.15%
1M Leistung:
+32.02%
6M Leistung:
+240.08%
1J Leistung:
+54.02%
1-Tages-Spanne:
$36.77
$45.50
1-Wochen-Bereich:
$28.01
$45.50
52-Wochen-Spanne:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
36.78 | 154.49M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Form 4 Cue Biopharma For: 10 July By Investing.com - Investing.com India
Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone - Stock Titan
Cue Biopharma (CUE) awards 21,800 restricted stock units to board director - Stock Titan
Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award - Stock Titan
Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant - Stock Titan
Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief - Stock Titan
Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief - Stock Titan
Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package - Stock Titan
Cue Biopharma Announces $50 Million Private Placement - TipRanks
Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle - TradingView
Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs - Stock Titan
Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE) - Seeking Alpha
Cue Biopharma Shares Rise on $50 Million Private Placement Pricing - Moomoo
CUE: Cue Biopharma Secures $50M in Private Placement - GuruFocus
Cue Biopharma (CUE) Secures $50M in Private Placement Financing - GuruFocus
Cue Biopharma to raise $50M in oversubscribed private placement - MSN
CUE BIOPHARMA ANNOUNCES $50.0 MILLION PRIVATE PLACEMENT - Moomoo
Cue Biopharma raises $50M in private placement By Investing.com - Investing.com South Africa
Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs - Stock Titan
Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management - Quiver Quantitative
Cue Biopharma Announces $50.0 Million Private Placement - GlobeNewswire Inc.
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma Inc outlines its immunotherapy approach for long-term investors - ad-hoc-news.de
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Signal Law Group Issues VRS Bulletin on Cue Biopharma, Inc. (CUE) - The Daily Tribune News
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Index - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Index - marketscreener.com
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Price to book forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma(CUE) Stock Options Chain | Quotes & News - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Enterprise value to revenue forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to earnings forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Long term debt to total equity ratio of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lin Shao-Lee - Moomoo
Cue Biopharma Stocklong-term strategy in immuno-oncology - AD HOC NEWS
Cue Biopharma Inc (CUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
CUE BIOPHARMA INC (CUE) Stock Chart - ChartMill
Cue Biopharma (NASDAQ: CUE) registers 551,724 pre-funded-warrant shares for resale - Stock Titan
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cue Biopharma | EFFECT: Others - Moomoo
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Inc (CUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):